Find a list of your saved stories here

Harlan Contract Research Services (CRS) and Bertin Pharma Sign Strategic Collaboration Agreement

Harlan Contract Research Services (CRS) and Bertin Pharma Sign Strategic Collaboration Agreement

1 photo
Save Story

Save stories to read later

Estimated read time: 2-3 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

ITINGEN, Switzerland--(BUSINESS WIRE)--Mar 4, 2014--Harlan Contract Research Services and Bertin Pharma, headquartered in Montigny-le-Bretonneux, France, announced a strategic partnership to offer a comprehensive package for early drug development. Under the agreement, the companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.

Through the alliance, Harlan CRS will strengthen its drug discovery and translational medicine offerings utilizing Bertin Pharma’s expertise in immunology and biomarkers.

“We welcome this strategic agreement with Bertin Pharma. Its expertise in the immunological sector is impressive and well-known in the industry,” said Manuela Leone, president of Harlan CRS.

“The new agreement benefits us both strategically and scientifically,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “Working together, we will provide the pharmaceutical industry the best team of scientists to increase the likelihood of success for new generation drugs.”

“For Bertin Pharma, this partnership will increase our international visibility and allow us to expand our services by integrating project management capabilities and expertise,” said Xavier Morge, managing director of Bertin Pharma.

“ PharmImmune, our joint offer with the French Alternative Energies and Atomic Energy Commission (CEA), is the perfect example of an innovative tool that we will be able to better utilize through our agreement with Harlan CRS,” said Pascal Clayette, head of the immuno-pharmacology department at Bertin Pharma.

About Harlan Contract Research Services Harlan Contract Research Services (CRS), a division of Harlan Laboratories, Inc., is a privately held provider of general and specialty toxicology services to the global chemical, agrochemical and pharmaceutical industries. With laboratory locations in Germany, Spain, Switzerland and the UK, Harlan CRS' focus is on providing customers with services to optimize product development. Please visit

About Bertin Pharma Bertin Pharma is a global solution provider offering R&D outsourcing services along with bioreagent tools in the fields of pharmacy, biotechnologies, cosmetics and nutrition. Through its innovative range of services, Bertin Pharma's comprehensive offerings cover the whole drug development value chain — from discovery to pharmaceutical development. Please visit or

Photos/Multimedia Gallery Available:

CONTACT: For inquiries concerning Harlan CRS, contact:

SCORR Marketing

Lea Studer, +1 308-237-5567


For inquiries concerning Bertin Pharma, contact:

Image 7

Nathalie Feld, +33 1 53 70 94 23


Bertin Pharma

Florence Fombertasse, +33 (0)139 306 225



SOURCE: Harlan Contract Research Services

Copyright Business Wire 2014

PUB: 03/04/2014 08:00 AM/DISC: 03/04/2014 08:00 AM

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Most recent Business stories

Related topics

Harlan Contract Research Services


    Catch up on the top news and features from, sent weekly.
    By subscribing, you acknowledge and agree to's Terms of Use and Privacy Policy.

    KSL Weather Forecast